March 29, 2024

Pharmaceutical CDMO Market Size To Cross USD 172.02 Bn By 2032

The global pharmaceutical CDMO market size accounted for US$ 94.17 Bn in 2022 and is projected to reach around USD 172.02 Bn by 2032, growing at a CAGR of 6.21% from 2023 to 2032.

Pharmaceutical CDMO Market Size 2023 To 2032

Report Summary

The global pharmaceutical CDMO market report provides a Point-by-Point and In-Depth analysis of global market size, regional and country-level market size, market share, segmentation market growth, competitive landscape, sales analysis, opportunities analysis, strategic market growth analysis, the impact of domestic and global market key players, value chain optimization, trade regulations, recent developments, product launches, area marketplace expanding, and technological innovations.

The study offers a comprehensive analysis on diverse features, including production capacities, demand, product developments, revenue generation, and sales in the pharmaceutical CDMO market across the globe.

A comprehensive estimate on the pharmaceutical CDMO market has been provided through an optimistic scenario as well as a conservative scenario, taking into account the sales of pharmaceutical CDMO during the forecast period. Price point comparison by region with global average price is also considered in the study.

Download Access to a Free Copy of Our Latest Sample Report@ https://www.precedenceresearch.com/sample/2936

Pharmaceutical CDMO Market Report Scope

Report CoverageDetails
Market Size in 2023USD 100.02 Billion
Market Size by 2032USD 172.02 Billion
Growth Rate from 2023 to 2032CAGR of 6.21%
Base Year2022
Forecast Period2023 to 2032
Segments CoveredBy Product, By Drug Product, By Dosage Form, By Indication, and By End-User
Regions CoveredNorth America, Europe, Asia-Pacific, Latin America and Middle East & Africa

Key Highlights: 

Reports Coverage: It incorporates key market sections, key makers secured, the extent of items offered in the years considered, worldwide containerized pharmaceutical CDMO market and study goals. Moreover, it contacts the division study gave in the report based on the sort of item and applications.

Market Outline: This area stresses the key investigations, market development rate, serious scene, market drivers, patterns, and issues notwithstanding the naturally visible pointers.

Market Production by Region: The report conveys information identified with import and fare, income, creation, and key players of every single local market contemplated are canvassed right now.

Also Read: Anti-Aging Cosmetics Market Size Analysis 2023 To 2032

Pharmaceutical CDMO Market Players

The report includes the profiles of key pharmaceutical CDMO market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information, key development in past five years.

Major companies operating in this area

  • Bushu Pharmaceuticals Ltd.
  • Nipro Corporation
  • Thermo Fisher Scientific Inc.
  • Samsung Biologics
  • Laboratory Corporation of America Holdings
  • Siegfried Holding Ag
  • Catalent, Inc
  • Lonza Group AG
  • Recipharm Ab
  • Piramal Pharma Solutions
  • Cordenpharma International
  • Cambrex Corporation
  • Wuxi Apptec

Market Segmentation

By Product

  • API
    • By Synthetic
      • Solid
      • Liquid
    • By Type
      • Traditional Active Pharmaceutical Ingredient (Traditional API)
      • Highly Potent Active Pharmaceutical Ingredient (HP-API)
      • Antibody Drug Conjugate (ADC)
      • Others
    • By Drug
      • Innovative
      • Generics
    • By Manufacturing
      • Continuous manufacturing
      • Batch manufacturing
    • Biotech

By Drug Product

  • Oral Solid Dose
  • Semi-solid dose
  • Liquid Dose
  • Others

By Dosage Form

  • Solid
    • Tablets
    • Capsules
    • Powder
  • Semi-Solid
    • Cream
    • Paste
    • Gel
  • Liquid Dose Formulation
    • Injectables
    • Sterile Vials
    • Single Use/Single Dose
    • Multi-Use
    • Ampules
    • Prefilled Syringes
    • Suspension
    • Emulsion
  • Gas Dose Formulation
    • Inhaler
    • Aerosols

By Indication

  • Cancer
  • Cardiovascular Disease
  • Diabetes
  • Pain
  • Respiratory disease
  • Other Disease

By End-User

  • Big Pharmaceutical Companies
  • Small & Medium-Sized Pharmaceutical Companies
  • Generic Pharmaceutical Companies
  • Other End Users

Regional Segmentation

  • North America (U.S., Canada, Mexico)
  • Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
  • Asia-Pacific (China, Japan, India, Southeast Asia and Rest of APAC)
  • Latin America (Brazil and Rest of Latin America)
  • Middle East and Africa (GCC, North Africa, South Africa, Rest of MEA)

Research Methodology

Secondary Research

It involves company databases such as Hoover’s: This assists us to recognize financial information, the structure of the market participants and industry’s competitive landscape.

The secondary research sources referred in the process are as follows:

  • Governmental bodies, and organizations creating economic policies
  • National and international social welfare institutions
  • Company websites, financial reports and SEC filings, broker and investor reports
  • Related patent and regulatory databases
  • Statistical databases and market reports
  • Corporate Presentations, news, press release, and specification sheet of Manufacturers

Primary Research

Primary research includes face-to-face interviews, online surveys, and telephonic interviews.

  • Means of primary research: Email interactions, telephonic discussions and Questionnaire-based research etc.
  • In order to validate our research findings and analysis, we conduct primary interviews of key industry participants. Insights from primary respondents help in validating the secondary research findings. It also develops Research Team’s expertise and market understanding.

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Pharmaceutical CDMO Market 

5.1. COVID-19 Landscape: Pharmaceutical CDMO Industry Impact

5.2. COVID 19 – Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Pharmaceutical CDMO Market, By Product

8.1. Pharmaceutical CDMO Market, by Product, 2023-2032

8.1.1. API

8.1.1.1. Market Revenue and Forecast (2020-2032)

Chapter 9. Global Pharmaceutical CDMO Market, By Drug Product

9.1. Pharmaceutical CDMO Market, by Drug Product, 2023-2032

9.1.1. Oral Solid Dose

9.1.1.1. Market Revenue and Forecast (2020-2032)

9.1.2. Semi-solid dose

9.1.2.1. Market Revenue and Forecast (2020-2032)

9.1.3. Liquid Dose

9.1.3.1. Market Revenue and Forecast (2020-2032)

9.1.4. Others

9.1.4.1. Market Revenue and Forecast (2020-2032)

Chapter 10. Global Pharmaceutical CDMO Market, By Dosage Form 

10.1. Pharmaceutical CDMO Market, by Dosage Form, 2023-2032

10.1.1. Solid

10.1.1.1. Market Revenue and Forecast (2020-2032)

10.1.2. Semi-Solid

10.1.2.1. Market Revenue and Forecast (2020-2032)

10.1.3. Liquid Dose Formulation

10.1.3.1. Market Revenue and Forecast (2020-2032)

10.1.4. Gas Dose Formulation

10.1.4.1. Market Revenue and Forecast (2020-2032)

Chapter 11. Global Pharmaceutical CDMO Market, By Indication

11.1. Pharmaceutical CDMO Market, by Indication, 2023-2032

11.1.1. Cancer

11.1.1.1. Market Revenue and Forecast (2020-2032)

11.1.2. Cardiovascular Disease

11.1.2.1. Market Revenue and Forecast (2020-2032)

11.1.3. Diabetes

11.1.3.1. Market Revenue and Forecast (2020-2032)

11.1.4. Pain

11.1.4.1. Market Revenue and Forecast (2020-2032)

11.1.5. Respiratory disease

11.1.5.1. Market Revenue and Forecast (2020-2032)

11.1.6. Other Disease

11.1.6.1. Market Revenue and Forecast (2020-2032)

Chapter 12. Global Pharmaceutical CDMO Market, By End-User

12.1. Pharmaceutical CDMO Market, by End-User, 2023-2032

12.1.1. Big Pharmaceutical Companies

12.1.1.1. Market Revenue and Forecast (2020-2032)

12.1.2. Small & Medium-Sized Pharmaceutical Companies

12.1.2.1. Market Revenue and Forecast (2020-2032)

12.1.3. Generic Pharmaceutical Companies

12.1.3.1. Market Revenue and Forecast (2020-2032)

12.1.4. Other End Users

12.1.4.1. Market Revenue and Forecast (2020-2032)

Chapter 13. Global Pharmaceutical CDMO Market, Regional Estimates and Trend Forecast

13.1. North America

13.1.1. Market Revenue and Forecast, by Product (2020-2032)

13.1.2. Market Revenue and Forecast, by Drug Product (2020-2032)

13.1.3. Market Revenue and Forecast, by Dosage Form (2020-2032)

13.1.4. Market Revenue and Forecast, by Indication (2020-2032)

13.1.5. Market Revenue and Forecast, by End-User (2020-2032)

13.1.6. U.S.

13.1.6.1. Market Revenue and Forecast, by Product (2020-2032)

13.1.6.2. Market Revenue and Forecast, by Drug Product (2020-2032)

13.1.6.3. Market Revenue and Forecast, by Dosage Form (2020-2032)

13.1.6.4. Market Revenue and Forecast, by Indication (2020-2032)

13.1.6.5. Market Revenue and Forecast, by End-User (2020-2032)

13.1.7. Rest of North America

13.1.7.1. Market Revenue and Forecast, by Product (2020-2032)

13.1.7.2. Market Revenue and Forecast, by Drug Product (2020-2032)

13.1.7.3. Market Revenue and Forecast, by Dosage Form (2020-2032)

13.1.7.4. Market Revenue and Forecast, by Indication (2020-2032)

13.1.7.5. Market Revenue and Forecast, by End-User (2020-2032)

13.2. Europe

13.2.1. Market Revenue and Forecast, by Product (2020-2032)

13.2.2. Market Revenue and Forecast, by Drug Product (2020-2032)

13.2.3. Market Revenue and Forecast, by Dosage Form (2020-2032)

13.2.4. Market Revenue and Forecast, by Indication (2020-2032)

13.2.5. Market Revenue and Forecast, by End-User (2020-2032)

13.2.6. UK

13.2.6.1. Market Revenue and Forecast, by Product (2020-2032)

13.2.6.2. Market Revenue and Forecast, by Drug Product (2020-2032)

13.2.6.3. Market Revenue and Forecast, by Dosage Form (2020-2032)

13.2.7. Market Revenue and Forecast, by Indication (2020-2032)

13.2.8. Market Revenue and Forecast, by End-User (2020-2032)

13.2.9. Germany

13.2.9.1. Market Revenue and Forecast, by Product (2020-2032)

13.2.9.2. Market Revenue and Forecast, by Drug Product (2020-2032)

13.2.9.3. Market Revenue and Forecast, by Dosage Form (2020-2032)

13.2.10. Market Revenue and Forecast, by Indication (2020-2032)

13.2.11. Market Revenue and Forecast, by End-User (2020-2032)

13.2.12. France

13.2.12.1. Market Revenue and Forecast, by Product (2020-2032)

13.2.12.2. Market Revenue and Forecast, by Drug Product (2020-2032)

13.2.12.3. Market Revenue and Forecast, by Dosage Form (2020-2032)

13.2.12.4. Market Revenue and Forecast, by Indication (2020-2032)

13.2.13. Market Revenue and Forecast, by End-User (2020-2032)

13.2.14. Rest of Europe

13.2.14.1. Market Revenue and Forecast, by Product (2020-2032)

13.2.14.2. Market Revenue and Forecast, by Drug Product (2020-2032)

13.2.14.3. Market Revenue and Forecast, by Dosage Form (2020-2032)

13.2.14.4. Market Revenue and Forecast, by Indication (2020-2032)

13.2.15. Market Revenue and Forecast, by End-User (2020-2032)

13.3. APAC

13.3.1. Market Revenue and Forecast, by Product (2020-2032)

13.3.2. Market Revenue and Forecast, by Drug Product (2020-2032)

13.3.3. Market Revenue and Forecast, by Dosage Form (2020-2032)

13.3.4. Market Revenue and Forecast, by Indication (2020-2032)

13.3.5. Market Revenue and Forecast, by End-User (2020-2032)

13.3.6. India

13.3.6.1. Market Revenue and Forecast, by Product (2020-2032)

13.3.6.2. Market Revenue and Forecast, by Drug Product (2020-2032)

13.3.6.3. Market Revenue and Forecast, by Dosage Form (2020-2032)

13.3.6.4. Market Revenue and Forecast, by Indication (2020-2032)

13.3.7. Market Revenue and Forecast, by End-User (2020-2032)

13.3.8. China

13.3.8.1. Market Revenue and Forecast, by Product (2020-2032)

13.3.8.2. Market Revenue and Forecast, by Drug Product (2020-2032)

13.3.8.3. Market Revenue and Forecast, by Dosage Form (2020-2032)

13.3.8.4. Market Revenue and Forecast, by Indication (2020-2032)

13.3.9. Market Revenue and Forecast, by End-User (2020-2032)

13.3.10. Japan

13.3.10.1. Market Revenue and Forecast, by Product (2020-2032)

13.3.10.2. Market Revenue and Forecast, by Drug Product (2020-2032)

13.3.10.3. Market Revenue and Forecast, by Dosage Form (2020-2032)

13.3.10.4. Market Revenue and Forecast, by Indication (2020-2032)

13.3.10.5. Market Revenue and Forecast, by End-User (2020-2032)

13.3.11. Rest of APAC

13.3.11.1. Market Revenue and Forecast, by Product (2020-2032)

13.3.11.2. Market Revenue and Forecast, by Drug Product (2020-2032)

13.3.11.3. Market Revenue and Forecast, by Dosage Form (2020-2032)

13.3.11.4. Market Revenue and Forecast, by Indication (2020-2032)

13.3.11.5. Market Revenue and Forecast, by End-User (2020-2032)

13.4. MEA

13.4.1. Market Revenue and Forecast, by Product (2020-2032)

13.4.2. Market Revenue and Forecast, by Drug Product (2020-2032)

13.4.3. Market Revenue and Forecast, by Dosage Form (2020-2032)

13.4.4. Market Revenue and Forecast, by Indication (2020-2032)

13.4.5. Market Revenue and Forecast, by End-User (2020-2032)

13.4.6. GCC

13.4.6.1. Market Revenue and Forecast, by Product (2020-2032)

13.4.6.2. Market Revenue and Forecast, by Drug Product (2020-2032)

13.4.6.3. Market Revenue and Forecast, by Dosage Form (2020-2032)

13.4.6.4. Market Revenue and Forecast, by Indication (2020-2032)

13.4.7. Market Revenue and Forecast, by End-User (2020-2032)

13.4.8. North Africa

13.4.8.1. Market Revenue and Forecast, by Product (2020-2032)

13.4.8.2. Market Revenue and Forecast, by Drug Product (2020-2032)

13.4.8.3. Market Revenue and Forecast, by Dosage Form (2020-2032)

13.4.8.4. Market Revenue and Forecast, by Indication (2020-2032)

13.4.9. Market Revenue and Forecast, by End-User (2020-2032)

13.4.10. South Africa

13.4.10.1. Market Revenue and Forecast, by Product (2020-2032)

13.4.10.2. Market Revenue and Forecast, by Drug Product (2020-2032)

13.4.10.3. Market Revenue and Forecast, by Dosage Form (2020-2032)

13.4.10.4. Market Revenue and Forecast, by Indication (2020-2032)

13.4.10.5. Market Revenue and Forecast, by End-User (2020-2032)

13.4.11. Rest of MEA

13.4.11.1. Market Revenue and Forecast, by Product (2020-2032)

13.4.11.2. Market Revenue and Forecast, by Drug Product (2020-2032)

13.4.11.3. Market Revenue and Forecast, by Dosage Form (2020-2032)

13.4.11.4. Market Revenue and Forecast, by Indication (2020-2032)

13.4.11.5. Market Revenue and Forecast, by End-User (2020-2032)

13.5. Latin America

13.5.1. Market Revenue and Forecast, by Product (2020-2032)

13.5.2. Market Revenue and Forecast, by Drug Product (2020-2032)

13.5.3. Market Revenue and Forecast, by Dosage Form (2020-2032)

13.5.4. Market Revenue and Forecast, by Indication (2020-2032)

13.5.5. Market Revenue and Forecast, by End-User (2020-2032)

13.5.6. Brazil

13.5.6.1. Market Revenue and Forecast, by Product (2020-2032)

13.5.6.2. Market Revenue and Forecast, by Drug Product (2020-2032)

13.5.6.3. Market Revenue and Forecast, by Dosage Form (2020-2032)

13.5.6.4. Market Revenue and Forecast, by Indication (2020-2032)

13.5.7. Market Revenue and Forecast, by End-User (2020-2032)

13.5.8. Rest of LATAM

13.5.8.1. Market Revenue and Forecast, by Product (2020-2032)

13.5.8.2. Market Revenue and Forecast, by Drug Product (2020-2032)

13.5.8.3. Market Revenue and Forecast, by Dosage Form (2020-2032)

13.5.8.4. Market Revenue and Forecast, by Indication (2020-2032)

13.5.8.5. Market Revenue and Forecast, by End-User (2020-2032)

Chapter 14. Company Profiles

14.1. Bushu Pharmaceuticals Ltd.

14.1.1. Company Overview

14.1.2. Product Offerings

14.1.3. Financial Performance

14.1.4. Recent Initiatives

14.2. Nipro Corporation

14.2.1. Company Overview

14.2.2. Product Offerings

14.2.3. Financial Performance

14.2.4. Recent Initiatives

14.3. Thermo Fisher Scientific Inc.

14.3.1. Company Overview

14.3.2. Product Offerings

14.3.3. Financial Performance

14.3.4. Recent Initiatives

14.4. Samsung Biologics

14.4.1. Company Overview

14.4.2. Product Offerings

14.4.3. Financial Performance

14.4.4. Recent Initiatives

14.5. Laboratory Corporation of America Holdings

14.5.1. Company Overview

14.5.2. Product Offerings

14.5.3. Financial Performance

14.5.4. Recent Initiatives

14.6. Siegfried Holding Ag

14.6.1. Company Overview

14.6.2. Product Offerings

14.6.3. Financial Performance

14.6.4. Recent Initiatives

14.7. Catalent, Inc

14.7.1. Company Overview

14.7.2. Product Offerings

14.7.3. Financial Performance

14.7.4. Recent Initiatives

14.8. Lonza Group AG

14.8.1. Company Overview

14.8.2. Product Offerings

14.8.3. Financial Performance

14.8.4. Recent Initiatives

14.9. Recipharm Ab

14.9.1. Company Overview

14.9.2. Product Offerings

14.9.3. Financial Performance

14.9.4. Recent Initiatives

14.10. Piramal Pharma Solutions

14.10.1. Company Overview

14.10.2. Product Offerings

14.10.3. Financial Performance

14.10.4. Recent Initiatives

Chapter 15. Research Methodology

15.1. Primary Research

15.2. Secondary Research

15.3. Assumptions

Chapter 16. Appendix

16.1. About Us

16.2. Glossary of Terms

Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Emailsales@precedenceresearch.com

Web: https://www.precedenceresearch.com

Blog: https://www.pharma-geek.com